PSC
BLTE

Patient Square Capital’s Belite Bio BLTE Stock Holding History

Patient Square Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
+116,684
New +$19.6M 3.3% 7

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Patient Square Capital's BLTE Position: Q1 2026 in Review

Patient Square Capital opened a new position in Belite Bio (BLTE) in Q1 2026: 116,684 shares worth $18.6M. The stake represents 3.3% of the portfolio and ranks #7 among its holdings.

75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Patient Square Capital held 116,684 shares of Belite Bio worth $18.6M as of Q1 2026.
  • Belite Bio was a new Patient Square Capital position in Q1 2026.
  • Belite Bio made up 3.3% of Patient Square Capital's portfolio in Q1 2026, its #7 holding.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.